Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug trial targets Cancer's genetic weakness

NCT ID NCT06400238

Summary

This study is testing whether a drug called copanlisib can help control advanced cancers that have a specific change in a gene called PTEN. The drug is given through an IV and aims to block signals that tell cancer cells to grow. It is for adults with various advanced or hard-to-treat cancers, including solid tumors, lymphoma, and multiple myeloma, who have this specific genetic feature.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • ECOG-ACRIN Cancer Research Group

    Philadelphia, Pennsylvania, 19103, United States

Conditions

Explore the condition pages connected to this study.